LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.
$0.85 +0.08 (10.88%)
As of 03/24/2023 16:00:01 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 09/21/2007
Outstanding shares: 16,646,593
Average volume: 165,627
Market cap: $12,787,913
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%